June 2002 Approvals
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
June Approvals
You may also be interested in...
KemPharm Taking Ritalin Prodrug Into Phase III For ADHD
Months after reaching agreement with FDA to refile the NDA for its abuse-deterrent opioid Apadaz, KemPharm has gotten the okay to take its prodrug of Ritalin into Phase III for ADHD.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product